rss
05-31-2015, 06:03 AM
Global Lung Cancer Therapeutics market to grow at a CAGR of 3.83% During 2015
About*Lung Cancer:-
Cancer occurs when, after undergoing cell transformation, **rmal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. **n-small cell lung cancer is the commonest type of lung cancer and forms almost 85-90 percent of the total cases diag**sed. It grows and spreads slowly. Smoking is considered as a major cause of lung cancer, though lung cancer also occurs in **n-*****rs. **n-small cell lung cancer is of three types: squamous cell (epidermoid) carci**ma, ade**carci**ma, and large cell (undifferentiated) carci**ma.
Global Lung Cancer Therapeutics market to grow at a CAGR of 3.83 percent over the period 2014-2019. (http://www.marketresearchstore.com/report/lung-cancer-therapeutics-market-1830#reportTableOfContent)
Small cell lung cancers form roughly 10-15 percent of all the diag**sed cases of lung cancer. There are two types of small cell lung cancer: small cell carci**ma and combined small cell carci**ma. It can be classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer can**t be cured using current therapies available in the market. Some of the common symptoms associated with lung cancer are chest pain, persistent cough, blood in sputum, fatigue, loss of appetite, weight loss, shortness of breath, and wheezing. Both small cell lung cancer and **n-small cell lung cancer are recurrent in nature, which are difficult to cure.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Lung Cancer Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various ***** used in the treatment of **n-small cell lung cancer and small cell lung cancer.
Request For Sample Report Here:
http://www.marketresearchstore.com/report/lung-cancer-therapeutics-market-1830#requestSample
The Global Lung Cancer Therapeutics market is segmented based on the type of molecule used for the
treatment of lung cancer, which include:
Biologics
Small molecules
In addition, the market is also segmented based on the route of administration followed for the treatment of lung cancer, which include:
Oral
Parenteral
Global Lung Cancer Therapeutics Market 2015 (http://www.marketresearchstore.com/report/lung-cancer-therapeutics-market-1830)-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Americas
APAC
EMEA
Key Vendors
AstraZeneca
Celgene
Eli Lilly
F. Hoffmann-La Roche
Pfizer
Other Prominent Vendors
Abbvie
Aetna
Agennix
Amgen
Boehringer Ingelheim
Celldex
Eisai
GlaxoSmithKline
GTx
Helsinn
IMClone
Merck Sero**
**vartis
Qiagen
OncoGenex
OSI Pharmaceuticals
Peregrine
Pierre Fabre
Sa**fi
Synta
Telik
Teva Pharmaceutical
Market Driver
High Unmet Need
For a full, detailed list, view our report
Market Challenge
High Cost of Therapy
For a full, detailed list, view our report
Market Trend
Personalized Medicine
For a full, detailed list, view our report
Personalized medicine is dependent on the genetic structure of the patient and can be developed accordingly.
Genentech, a subsidiary of F. Hoffmann-La Roche, obtained approval for Tarceva, which is the first FDA approved therapy for the treatment of **n-small cell lung cancer in the US. It is approved for the indication of Epidermal Growth Factor Receptor (EGFR) mutation-positive metastatic **n-small cell lung cancer.
“Research efforts and investment are expected to increase as organizations like the Lung Cancer Alliance in the US generate awareness of the disease,” says Faisal Ghaus.
“These associations provide support to patients in terms of access to medicines and reimbursement for testing and diag**sis of the disease. Additionally, they provide funding for research related to lung cancer, which will ultimately help the Lung Cancer Therapeutics Market grow through the projected period. ”
The post Global Lung Cancer Therapeutics market to grow at a CAGR of 3.83% During 2015 (http://www.medgadget.com/2015/05/global-lung-cancer-therapeutics-market-grow-cagr-3-83-2015.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=opU1lknSkbY:dZAv7lJdcUs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=opU1lknSkbY:dZAv7lJdcUs:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=opU1lknSkbY:dZAv7lJdcUs:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=opU1lknSkbY:dZAv7lJdcUs:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/opU1lknSkbY
About*Lung Cancer:-
Cancer occurs when, after undergoing cell transformation, **rmal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. **n-small cell lung cancer is the commonest type of lung cancer and forms almost 85-90 percent of the total cases diag**sed. It grows and spreads slowly. Smoking is considered as a major cause of lung cancer, though lung cancer also occurs in **n-*****rs. **n-small cell lung cancer is of three types: squamous cell (epidermoid) carci**ma, ade**carci**ma, and large cell (undifferentiated) carci**ma.
Global Lung Cancer Therapeutics market to grow at a CAGR of 3.83 percent over the period 2014-2019. (http://www.marketresearchstore.com/report/lung-cancer-therapeutics-market-1830#reportTableOfContent)
Small cell lung cancers form roughly 10-15 percent of all the diag**sed cases of lung cancer. There are two types of small cell lung cancer: small cell carci**ma and combined small cell carci**ma. It can be classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer can**t be cured using current therapies available in the market. Some of the common symptoms associated with lung cancer are chest pain, persistent cough, blood in sputum, fatigue, loss of appetite, weight loss, shortness of breath, and wheezing. Both small cell lung cancer and **n-small cell lung cancer are recurrent in nature, which are difficult to cure.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Lung Cancer Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various ***** used in the treatment of **n-small cell lung cancer and small cell lung cancer.
Request For Sample Report Here:
http://www.marketresearchstore.com/report/lung-cancer-therapeutics-market-1830#requestSample
The Global Lung Cancer Therapeutics market is segmented based on the type of molecule used for the
treatment of lung cancer, which include:
Biologics
Small molecules
In addition, the market is also segmented based on the route of administration followed for the treatment of lung cancer, which include:
Oral
Parenteral
Global Lung Cancer Therapeutics Market 2015 (http://www.marketresearchstore.com/report/lung-cancer-therapeutics-market-1830)-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Americas
APAC
EMEA
Key Vendors
AstraZeneca
Celgene
Eli Lilly
F. Hoffmann-La Roche
Pfizer
Other Prominent Vendors
Abbvie
Aetna
Agennix
Amgen
Boehringer Ingelheim
Celldex
Eisai
GlaxoSmithKline
GTx
Helsinn
IMClone
Merck Sero**
**vartis
Qiagen
OncoGenex
OSI Pharmaceuticals
Peregrine
Pierre Fabre
Sa**fi
Synta
Telik
Teva Pharmaceutical
Market Driver
High Unmet Need
For a full, detailed list, view our report
Market Challenge
High Cost of Therapy
For a full, detailed list, view our report
Market Trend
Personalized Medicine
For a full, detailed list, view our report
Personalized medicine is dependent on the genetic structure of the patient and can be developed accordingly.
Genentech, a subsidiary of F. Hoffmann-La Roche, obtained approval for Tarceva, which is the first FDA approved therapy for the treatment of **n-small cell lung cancer in the US. It is approved for the indication of Epidermal Growth Factor Receptor (EGFR) mutation-positive metastatic **n-small cell lung cancer.
“Research efforts and investment are expected to increase as organizations like the Lung Cancer Alliance in the US generate awareness of the disease,” says Faisal Ghaus.
“These associations provide support to patients in terms of access to medicines and reimbursement for testing and diag**sis of the disease. Additionally, they provide funding for research related to lung cancer, which will ultimately help the Lung Cancer Therapeutics Market grow through the projected period. ”
The post Global Lung Cancer Therapeutics market to grow at a CAGR of 3.83% During 2015 (http://www.medgadget.com/2015/05/global-lung-cancer-therapeutics-market-grow-cagr-3-83-2015.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=opU1lknSkbY:dZAv7lJdcUs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=opU1lknSkbY:dZAv7lJdcUs:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=opU1lknSkbY:dZAv7lJdcUs:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=opU1lknSkbY:dZAv7lJdcUs:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/opU1lknSkbY